Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice
Transplant International · 2025
DOI: 10.3389/ti.2025.15433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von G Siracusano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Induced Pluripotent Stem Cells, Antibodies, Monoclonal, Immune Tolerance. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Induced pluripotent stem cell (iPSC)-derived pancreatic islets represent a promising therapeutic approach for restoring insulin independence in type 1 diabetes (T1D). However, their clinical success remains critically dependent on overcoming rejection mediated by innate and adaptive immune responses. Current immunosuppressive therapies pose significant long-term risks and only partially control alloimmune and autoimmune reactions. Targeted immunomodulation using monoclonal antibodies is a safer, more precise alternative. Here, we explored the impacts of blocking CD276 (B7-H3) and CD155 (PVR), activating ligands involved in immune recognition and regulation, on the survival and in vivo maturation of iPSC-derived endocrine progenitors (EPs) into functional pancreatic islets. Using a humanized mouse model, we demonstrated that dual blockade of CD276 and CD155 markedly reduced NK cell-mediated graft rejection, prevented CD14 + monocyte activation, and limited overall immune infiltration. In addition, CD155 blockade increased PD-1 levels on activated CD8 + T cells and significantly enhanced regulatory T cell (Treg) expansion and function, thereby promoting graft tolerance. Combined treatment prolonged engraftment and facilitated the maturation of EPs into functional, insulin-secreting cells, as indicated by increased human C-peptide levels and glucose responsiveness 4 weeks post-transplantation. Our findings highlight CD276/CD155 blockade as a novel immunomodulatory strategy to support tolerance and the functional maturation of iPSC-derived pancreatic grafts in T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
- University Vita-Salute San Raffaele, Milan, Italy.
- Division of Immunology, Transplantation and Infectious Disease (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Zitieren
APA
Siracusano, G., Deambrogio, F., Sordi, V., Malnati, M., Piemonti, L., & Chimienti, R. (2025). Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice. Transplant International. https://doi.org/10.3389/ti.2025.15433
Vancouver
Siracusano G, Deambrogio F, Sordi V, Malnati M, Piemonti L, Chimienti R. Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice. Transplant International. 2025. doi:10.3389/ti.2025.15433
BibTeX
@article{Siracusano2025,
author = {Siracusano, G and Deambrogio, F and Sordi, V and Malnati, M and Piemonti, L and Chimienti, R},
title = {Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.15433}
}
EUVIMED